Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2023

24.02.2023 | Case Study

Intraoperative radiotherapy for brain metastases: first-stage results of a single-arm, open-label, phase 2 trial

verfasst von: Douglas Guedes de Castro, Paulo Issamu Sanematsu Jr., Antônio Cassio Assis Pellizzon, Sérgio Hideki Suzuki, Ricardo Cesar Fogaroli, José Eduardo Souza Dias Jr., Guilherme Rocha Melo Gondim, Daniel Alvarez Estrada, Maria Letícia Gobo Silva, Marcio Saquy Rassi, Michael Jenwei Chen, Richard Giacomelli, Henderson Ramos, Elson Santos Neto, Carolina Humeres Abrahão, Tharcisio Machado Coelho, Liao Shin Yu, Cassio de Queiroz Tannous, Vinicius Fernando Calsavara, Frank Anton Giordano, Jean Gonçalves de Oliveira

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Focal stereotactic radiosurgery to the surgical cavity lowers local recurrence after resection of brain metastases (BM). To evaluate local control (LC) and brain disease control (BDC) after intraoperative radiotherapy (IORT) for resected BM.

Methods

Adult patients with completely resected single supratentorial BM were recruited and underwent IORT to the cavity with a prescribed dose of 18 Gy to 1 mm-depth. Primary endpoints were actuarial LC and BDC. Local failure (LF) and distant brain failure (DBF), with death as a competing risk, were estimated. Secondary endpoints were overall survival (OS) and incidence of radiation necrosis (RN). Simon’s two-stage design was used and estimated an accrual of 10 patients for the first-stage analysis and a LC higher than 63% to proceed to second stage. We report the final analysis of the first stage.

Results

Between June 2019 to November 2020, 10 patients were accrued. Median clinical and imaging FU was 11.2 and 9.7 months, respectively. Median LC was not reached and median BDC was 5 months. The 6-month and 12-month LC was 87.5%. The 6-month and 12-month BDC was 39% and 13%, respectively. Incidence of LF at 6 and 12 months was 10% and of DBF at 6 and 12 months was 50% and 70%, respectively. Median OS was not reached. The 6-month and 12-month OS was 80%. One patient had asymptomatic RN.

Conclusion

IORT for completely resected BM is associated with a potential high local control and low risk of RN, reaching the pre-specified criteria to proceed to second stage and warranting further studies.
Literatur
1.
Zurück zum Zitat Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: report on the updated diagnosis-specific graded Prognostic Assessment and Definition of the eligibility quotient. J Clin Oncol 38(32):3773–3784CrossRefPubMedPubMedCentral Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: report on the updated diagnosis-specific graded Prognostic Assessment and Definition of the eligibility quotient. J Clin Oncol 38(32):3773–3784CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044CrossRefPubMed Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044CrossRefPubMed
3.
Zurück zum Zitat Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401–409CrossRefPubMedPubMedCentral Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401–409CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Mahajan A, Ahmed S, McAleer MF et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048CrossRefPubMedPubMedCentral Mahajan A, Ahmed S, McAleer MF et al (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060CrossRefPubMedPubMedCentral Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Weil RJ, Mavinkurve GG, Chao ST et al (2015) Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes. J Neurosurg 122(4):825–832CrossRefPubMed Weil RJ, Mavinkurve GG, Chao ST et al (2015) Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes. J Neurosurg 122(4):825–832CrossRefPubMed
7.
Zurück zum Zitat Cifarelli CP, Brehmer S, Vargo JA et al (2019) Intraoperative (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145(2):391–397CrossRefPubMedPubMedCentral Cifarelli CP, Brehmer S, Vargo JA et al (2019) Intraoperative (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145(2):391–397CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Vargo JA, Sparks KM, Singh R, Jacobson GM, Hack JD, Cifarelli CP (2018) Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to post-operative stereotactic radiosurgery. J Neuroncol 140(2):413–420CrossRef Vargo JA, Sparks KM, Singh R, Jacobson GM, Hack JD, Cifarelli CP (2018) Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to post-operative stereotactic radiosurgery. J Neuroncol 140(2):413–420CrossRef
9.
Zurück zum Zitat Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 16(3):1141–1154CrossRef Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics 16(3):1141–1154CrossRef
10.
Zurück zum Zitat Kahl KH, Balagiannis N, Höck M et al (2021) Intraoperative with low-energy x-rays after neurosurgical resection of brain metastases - an Augsburg University Medical Center experience. Strahlen Onkol 197(12):1124–1130CrossRef Kahl KH, Balagiannis N, Höck M et al (2021) Intraoperative with low-energy x-rays after neurosurgical resection of brain metastases - an Augsburg University Medical Center experience. Strahlen Onkol 197(12):1124–1130CrossRef
11.
Zurück zum Zitat Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387–395CrossRefPubMed Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387–395CrossRefPubMed
12.
Zurück zum Zitat Robbins JR, Ryu S, Kalkanis S et al (2012) Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery 71(5):937–943CrossRefPubMed Robbins JR, Ryu S, Kalkanis S et al (2012) Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery 71(5):937–943CrossRefPubMed
13.
Zurück zum Zitat Diehl CD, Pigorsch SU, Gempt J et al (2023) Low-energy X-Ray Intraoperative Radiation Therapy (Lex-IORT) for resected brain metastases: a Single-Institution experience. Cancers 15:14CrossRef Diehl CD, Pigorsch SU, Gempt J et al (2023) Low-energy X-Ray Intraoperative Radiation Therapy (Lex-IORT) for resected brain metastases: a Single-Institution experience. Cancers 15:14CrossRef
14.
Zurück zum Zitat Patel KR, Burri SH, Asher AL et al (2016) Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metástases. Neurosurgery 79(2):279–285CrossRefPubMed Patel KR, Burri SH, Asher AL et al (2016) Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metástases. Neurosurgery 79(2):279–285CrossRefPubMed
15.
Zurück zum Zitat Prabhu RS, Patel KR, Press RH et al (2019) Preoperative vs postoperative Radiosurgery for Resected Brain Metastases: a review. Neurosurgery 84(1):19–29CrossRefPubMed Prabhu RS, Patel KR, Press RH et al (2019) Preoperative vs postoperative Radiosurgery for Resected Brain Metastases: a review. Neurosurgery 84(1):19–29CrossRefPubMed
16.
Zurück zum Zitat Herskind C, Wenz F, Giordano FA (2017) Immunotherapy Combined with large fractions of Radiotherapy: stereotactic radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol 7:147CrossRefPubMedPubMedCentral Herskind C, Wenz F, Giordano FA (2017) Immunotherapy Combined with large fractions of Radiotherapy: stereotactic radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol 7:147CrossRefPubMedPubMedCentral
Metadaten
Titel
Intraoperative radiotherapy for brain metastases: first-stage results of a single-arm, open-label, phase 2 trial
verfasst von
Douglas Guedes de Castro
Paulo Issamu Sanematsu Jr.
Antônio Cassio Assis Pellizzon
Sérgio Hideki Suzuki
Ricardo Cesar Fogaroli
José Eduardo Souza Dias Jr.
Guilherme Rocha Melo Gondim
Daniel Alvarez Estrada
Maria Letícia Gobo Silva
Marcio Saquy Rassi
Michael Jenwei Chen
Richard Giacomelli
Henderson Ramos
Elson Santos Neto
Carolina Humeres Abrahão
Tharcisio Machado Coelho
Liao Shin Yu
Cassio de Queiroz Tannous
Vinicius Fernando Calsavara
Frank Anton Giordano
Jean Gonçalves de Oliveira
Publikationsdatum
24.02.2023
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-023-04266-x

Weitere Artikel der Ausgabe 1/2023

Journal of Neuro-Oncology 1/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.